Rosiglitazone and Cardiovascular Risk

Abstract

The study by Nissen and Wolski (June 14 issue)¹ shows increased rates of myocardial infarction and death from cardiovascular causes associated with rosiglitazone treatment for type 2 diabetes. The authors' results are intriguing because a simple calculation of the pooled data shows a higher rate of myocardial infarction in the control group than in the rosiglitazone group (0.59% vs. 0.55%). In contrast, the Peto odds ratio for myocardial infarction of 1.43 (95% confidence interval [CI], 1.03 to 1.98) that is reported in the article shows a significantly increased risk in the rosiglitazone group.